Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

E6005 · RVT-501

Small molecule · developed by Organon and Co

Phase 1/2 Most advanced trial (none active)
OGN Developer
2 Registered trials

What is E6005?

E6005 (also known as RVT-501) is a topical ointment studied in atopic dermatitis, applied at concentrations from 0.01% to 0.2%.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
RVT-501
Drug type
Small molecule
Therapy area
Dermatology
Developer
Organon and Co (OGN)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2
UNII
TO043KKB9C

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT02094235 Phase 1/2 Atopic Dermatitis Completed OGN
NCT01179880 Phase 1/2 Atopic Dermatitis Completed OGN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Atopic Dermatitis

More from Organon and Co

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the OGN page.

Follow OGN, the company behind E6005

See OGN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

OGN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.